Stage IV lung cancer: Is cure possible?

Thippeswamy, Ravi; Noronha, Vanita; Krishna, Vidya; Joshi, Amit; Bal, Munita; Purandare, Nilendu; Rangarajan, Venkatesh; Pramesh, C S; Jiwnani, Sabita; Prabhash, Kumar

doi:10.4103/0971-5851.116207

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death in the world, and it accounts for approximately 85% of all lung cancer diagnoses [1]. Advanced stage (IV) NSCLC is known to metastasize to a number of organs including the brain [2][3][4][5][6]. The identification of epidermal growth factor receptor (EGFR) mutations as one of the driving factors in NSCLC allowed the development of targeted therapy for NSCLC patients.…”

Section: Introductionmentioning

confidence: 99%

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Hoppe

Jamalpoor

Rood

et al. 2019

Pharmacological Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Hoppe

Jamalpoor

Rood

et al. 2019

Pharmacological Research

View full text Add to dashboard Cite

“…The patient was treated with palliative radiotherapy plus dexamethasone and analgesics as the treatment options in this stage of advanced bronchogenic carcinoma (T4 N3 M1C) should focus on palliative therapy [16]. Despite that, he died after 3 weeks of treatment.…”

Section: Discussionmentioning

confidence: 99%

Bone Metastasis As the Initial Presentation of a Hidden Bronchogenic Carcinoma

Ibraheem¹

2022

Cureus

View full text Add to dashboard Cite

Primary malignant bone tumours are on the whole rare, while secondary bone tumours are much more common. Up to 40% of bone metastases are associated with lung cancer. This case report highlights a rare presentation of metastatic bone disease as the initial presentation of a primary lung malignancy and only very few cases were mentioned in literature with the same presentation of no clinical signs of the primary lung pathology, except for an unexpected radiological finding of a suspicious lung lesion.An 85-year-old gentleman presented with a progressive lower backache radiating to both lower limbs over a period of 4 weeks associated with difficulty in walking, significant weight loss, and decreased appetite. A skeletal survey showed only spondylolisthesis. However, no clinical improvement was noticed with conventional therapy. Examination of the respiratory, gastrointestinal, and genitourinary systems was normal. Ultrasonography of the abdomen and pelvis, and the findings of the colonoscopy did not add anything. During the third week of follow-up, the patient reported unbearable severe pain in the left arm. A plain radiograph revealed a pathological fracture of the humerus. Secondary bone metastasis was suspected. Although the patient was a non-smoker and there were no clinical signs of underlying lung disease, a simple plain chest radiograph, unexpectedly, showed a suspicious right lower lobe lesion. Therefore, a contrastenhanced computerized tomography (CT) scan for the chest, abdomen, and pelvis was done which revealed a right lower lobe lesion of bronchogenic carcinoma with distant metastasis. Unfortunately, the patient died after 3 weeks of palliative therapy when he was admitted to the hospital with acute renal failure and septic shock.Bone metastases in lung cancer predict a poor prognosis and short-term survival. The diagnosis of such a challenging presentation requires a high index of suspicion. If the patient had been sent for a plain chest radiograph at first, lots of time and effort could be saved in reaching the diagnosis without the need for further sophisticated or invasive diagnostic procedures.

show abstract

“…The above case is an example suggesting the feasibility of CRT in M1a disease in the absence of extrathoracic disease. A similar case of M1a disease of squamous histology was treated with curative intent with neoadjuvant chemotherapy followed by surgery, another deviation from the standard guidelines [ 8 ]. In such circumstances, thinking outside the box may help prolong survival in selected patients.…”

Section: Discussionmentioning

confidence: 99%

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible

Kedia

Garcia

Dhar

2015

Cureus

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death in the United States with a five-year survival of 16.8% for all stages and median survival of four months for Stage IV disease. We report a case of a 54-year-old male with a seven-year survival after being diagnosed with Stage IV epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative adenocarcinoma of the lung, demonstrating an exceptional response to treatment.

show abstract

Stage IV lung cancer: Is cure possible?

Cited by 8 publications

References 26 publications

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)

Bone Metastasis As the Initial Presentation of a Hidden Bronchogenic Carcinoma

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible

Contact Info

Product

Resources

About